MANNKIND CORP Form 8-K May 04, 2012

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2012

# **MannKind Corporation**

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction

000-50865 (Commission 13-3607736 (IRS Employer Identification No.)

of incorporation or organization)

File Number)

#### 28903 North Avenue Paine

Valencia, California 91355 (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (661) 775-5300

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On April 30, 2012, James Shannon, M.D., MRCP (UK), a member of the Board of Directors of MannKind Corporation (the Company ), informed the Company that he was resigning from the Board of Directors effective May 1, 2012 in connection with his appointment as Corporate Chief Medical Officer of GlaxoSmithKline plc.

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### MANNKIND CORPORATION

By: /s/ DAVID THOMSON, PH.D., J.D.
Name: David Thomson, Ph.D., J.D.
Title: Corporate Vice President, General Counsel

and Secretary

Dated: May 4, 2012